<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200418047125N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-08-06</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>The effect of coconut oil consumption on improving the weakness of COVID-19 patients</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation the Effect of Coconut Oil as a complementary therapy on fatigue in Covid-19 patients A randomized double-blind pilot study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>28</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/56282</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, randomization will be performed by simple randomization method using random numbers derived from Excel program. First, the total sample size and number of groups are entered into the software. The software output includes a list that randomly assigns patients to two groups A (intervention) and B (control). Patients are distributed according to the time of referral according to the list of the mentioned group until the end of sampling.
Random sequence generation in Excel software is done using the RANDBETWEEN () function
According to this method, each of the cells is randomly assigned a code of 0 or 1. Cells with code 0 belong to the intervention group and cells with code 1 belong to the control group.
Patients are assigned to one of the groups according to the generated list, Blinding description: This study is performed as a double-blind study. The researcher and the patients participating in the study are unaware of the content of the drug. Drugs are prepared and coded in similar packages and provided to the executor for the prescription to patients. The outcome assessment is done by a person who is blind to the allocation process.</study_design>
      <phase>2</phase>
      <hc_freetext>COVID- 19.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In addition to routine treatment, 30 cc (every 12 hours 15 cc) of virgin coconut oil is consumed orally in pure form or with milk or soup. Routine treatment includes acetaminophen 500 mg tablets every 8 In case of pain or fever, take one vitamin 1000 microgram tablet daily and recommend rest, proper nutrition, and adequate fluid intake. Intervention 2: Control group: In addition to routine treatment,  patients in the control group consume 30 cc (15 cc every 12 hours) of placebo solution (containing mineral water + coconut flavoring) in pure form or with milk or soup.Routine treatment includes acetaminophen 500 mg tablets every 8 In case of pain or fever, take one vitamin 1000 microgram tablet daily and recommend rest, proper nutrition, and adequate fluid intake.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information and data on the primary and secondary outcomes of patients will be shared after being identified.

When:
Ability to access data about 6 months after printing the results

To whom:
All researchers will be allowed access to the data after reviewing it by the person in charge of the study.

Conditions:
Any analysis of the data will be possible only with the permission of the corresponding author

Where to obtain:
corresponding Author

How to obtain:
The person submits their request, the corresponding author evaluates the accessibility and if possible the access to the data will be granted.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ghazaleh Ghorbannezhad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 4, Emad khorasani 7, piroozi 72, piroozi Blvd, Mashhad</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9179973148</zip>
        <telephone>+98 51 3891 8263</telephone>
        <email>ghorbannezhadg962@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Ali Reza Derakhshan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mashhad, University of Medical Sciences, Faculty of Iranian and Complementary Medicine</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9177899191</zip>
        <telephone>+98 51 3884 8931</telephone>
        <email>Derakhshanar@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients 18-80 years old
have been diagnosed COVID-19, According to the information registration system of Mashhad University of Medical Sciences
hospitalized at home</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of Allergy to coconut and its derivatives
Dissatisfaction with inclusion in the study
Severe illness and need for hospitalization</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>U07.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>COVID-19, virus identified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In addition to routine treatment, 30 cc (every 12 hours 15 cc) of virgin coconut oil is consumed orally in pure form or with milk or soup. Routine treatment includes acetaminophen 500 mg tablets every 8 In case of pain or fever, take one vitamin 1000 microgram tablet daily and recommend rest, proper nutrition, and adequate fluid intake.</i_keyword>
      <i_keyword>Control group: In addition to routine treatment,  patients in the control group consume 30 cc (15 cc every 12 hours) of placebo solution (containing mineral water + coconut flavoring) in pure form or with milk or soup.Routine treatment includes acetaminophen 500 mg tablets every 8 In case of pain or fever, take one vitamin 1000 microgram tablet daily and recommend rest, proper nutrition, and adequate fluid intake.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Weakness. Timepoint: End of the first and second week. Method of measurement: According to the VAS criteria.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Fever. Timepoint: At the end of the first and second week. Method of measurement: Thermometer.</sec_outcome>
      <sec_outcome>Intensity and frequency of cough. Timepoint: At the end of the first and second week. Method of measurement: Visual Scale Scoring or VAS.</sec_outcome>
      <sec_outcome>Myalgia. Timepoint: At the end of the first and second week. Method of measurement: Visual Scale Scoring or VAS.</sec_outcome>
      <sec_outcome>Respiratory rate. Timepoint: At the end of the first and second week. Method of measurement: count respiratory rate in one minute.</sec_outcome>
      <sec_outcome>Hospitalization. Timepoint: At the end of the first and second week. Method of measurement: The ratio of the number of cases leading to hospitalization to the total number of patients in each group.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-04-24</approval_date>
        <contact_name>Ethics committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>School of Medicine, Mashhad University of Medical Sciences,Vakilabad St., Mashhad Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
